Eli Lilly Grants Early Access to Revolutionary Weight Loss Drug, Retatrutide
On August 4, 2026, pharmaceutical titan Eli Lilly declared the initiation of its expanded access program for Retatrutide. This experimental, next-generation obesity drug will be available to select patients prior to its U.S. FDA approval. The announcement comes in response to reports by STAT News of numerous physicians seeking access for their patients but receiving no response from the company.
Retatrutide, a triple hormone receptor agonist, engages GLP-1, GIP, and glucagon pathways simultaneously. This makes it significantly more potent than existing weight-loss drugs like Lilly’s own Zepbound (two pathways) and Novo Nordisk’s Wegovy (one pathway). During a crucial Phase 3 trial, participants on the highest 12 mg dose lost an average of 28.3% of their body weight over a span of 80 weeks.
To be eligible for the program, patients must meet the following criteria:
- Be aged 18 or older
- Have refractory obesity with a BMI ≥ 35 despite tolerating the highest approved dose of weight management therapy
- Have at least two serious or life-threatening obesity-related complications
Applications must be submitted by a treating physician — patients cannot apply directly. Lilly is planning to file for FDA approval in the first quarter of 2027.
Source: Reuters / Yahoo News – August 3, 2026